AstraZeneca's revenue has grown from $12.9B in 2024Q2 to $16.0B in 2026Q3, though year-over-year growth has decelerated to 5.3% in the latest quarter from double-digit rates in 2025, which suggests the top-line momentum may be slowing.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has risen from $12.9B to $16.0B over ten quarters, but net margin has swung between 10.1% and 21.5% and EPS has been volatile, suggesting earnings quality and cost absorption warrant further investigation.
AstraZeneca has over 20 Phase III readouts expected in 2026, including positive Q1 results for tozorakimab and Enhertu.
The oncology division contributes approximately 45% of revenues, supported by blockbuster drugs and a deep pipeline.
Q1 2026 revenues increased by 8% year-on-year, with operating profit rising 17% and guidance for mid-to-high single-digit revenue growth.
The US patent expiry for Farxiga in 2026 is expected to cause revenue declines, with Brilinta already seeing a 65% drop due to generics.
US drug pricing policies and China's Volume-Based Purchasing could impact future drug launches and profitability.
Not all Phase III trials may succeed, as evidenced by the Ceralasertib LATIFY failure, raising concerns about revenue generation.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 30, 2026 | $2.79+7.3% vs $2.60 | $16.2B+1.3% vs $16.0B |
Q3 2026 Jul 27, 2026 | $2.63+5.2% vs $2.50 | $15.4B-0.3% vs $15.4B |
Q2 2026 Apr 29, 2026 | $2.58+0.4% vs $2.57 | $15.3B+2.4% vs $14.9B |
Q1 2026 Feb 10, 2026 | $2.12+1.4% vs $2.09 | $15.5B+0.4% vs $15.4B |
AstraZeneca Plc (NYSE: AZN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1 year price target
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
International Assets Investment Management LLC boosted its stake in AstraZeneca Plc (NYSE: AZN) by 1,564.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 28,785 shares of the company's stock after purchasing an additional 27,056 shares during the period. International Assets Investment Management LLC's holdings in
Bank Julius Baer and Co. Ltd Zurich bought a new stake in AstraZeneca Plc (NYSE: AZN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,929,102 shares of the company's stock, valued at approximately $314,403,000. Bank Julius Baer and Co. Ltd
Benchmark AZN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AstraZeneca PLC (AZN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $186.43 | $144.48B | 14.25 | 8.63% | 17.46% | 22.89% | 3.41% | |
| $29.39 | $167.51B | 21.61 | -1.65% | 6.34% | 4.59% | 5.85% | |
| $146.71 | $362.35B | 20.15 | 1.18% | 4.78% | 6.59% | 2.22% | |
| $1354.00 | $1.28T | 59.00 | 44.7% | 31.9% | 83.64% | 0.44% | |
| $62.14 | $126.89B | 18.01 | -0.22% | 18.47% | 43.84% | 3.98% | |
| $291.31 | $514.68B | 122.92 | 8.57% | 15.68% | 286.66% | 2.26% |
AstraZeneca PLC (AZN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AZN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AstraZeneca PLC (AZN) stock FAQ — growth, dividends, profitability & financials explained
AstraZeneca PLC (AZN) reported $62.17B in revenue over the trailing twelve months. Revenue was $58.74B in fiscal year 2025. That is 540% more than the $9.18B of fiscal year 1996.
AstraZeneca PLC (AZN) grew revenue by 8.6% in fiscal year 2025, compared with the prior fiscal year.
Yes. AstraZeneca PLC (AZN) earned $10.99B in net income over the trailing twelve months (a 17.7% net margin).
Yes. AstraZeneca PLC (AZN) pays a dividend that yields 3.41% at the current price, a moderate yield.
AstraZeneca PLC (AZN) had a return on equity (ROE) of 22.9% in fiscal year 2025. That is well above the market's typical 10-15%.
AstraZeneca PLC (AZN) generated $9.32B in free cash flow over the trailing twelve months.
